Strategic Funding for Launching Arbli
TAMPA, FL – SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a dynamic holding company focused on enhancing pharmaceutical products for patients and healthcare professionals, has announced a significant draw from its Equity Line of Credit (ELOC). This funding aims to support the upcoming commercial launch of Arbli™, a groundbreaking losartan potassium oral suspension. However, the company has also declared a temporary pause on further draws until either the stock price reaches $10 per share or a period of 30 trading days passes, whichever comes first.
Significance of FDA Approval
This strategic funding decision coincides with an important milestone: the U.S. Food and Drug Administration (FDA) has granted approval for Arbli™, recognizing it as the first FDA-approved ready-to-use oral liquid form of losartan. This approval is a pivotal moment for Scienture Holdings, as it marks the company’s accomplishment in addressing a significant market need for alternative formulations of medications.
“The recent FDA approval is a transformative achievement for us,” said Suren Ajjarapu, Chairman of the Board at Scienture Holdings. “We have made the decision to utilize our ELOC to ensure we have the necessary resources for launching Arbli™ while also taking a prudent approach to manage shareholder interests during this critical phase.”
Future Prospects for Arbli™
Scienture Holdings is committed to carefully managing its capital and has temporarily suspended ELOC draws as it anticipates the commercialization of Arbli™. This strategic pause demonstrates confidence in the company's potential to flourish, especially considering the anticipated demand for Arbli™.
Narasimhan Mani, President of Scienture, LLC, highlighted the importance of this financial strategy, stating, “This approach allows us to balance our financial commitments while ensuring that we are well-positioned for the commercial success of Arbli™, which can substantially meet the needs of patients requiring a liquid formulation of losartan.”
Commercial Launch Timeline
The company plans to introduce Arbli™ to patients across the U.S. in the third quarter of 2025. This innovative formulation is designed for the treatment of hypertension in patients aged six and older. Additionally, it is intended to reduce the risk of stroke in patients who have hypertension alongside left ventricular hypertrophy and is used in treating diabetic nephropathy in qualified patients with type 2 diabetes.
Understanding Arbli™
Arbli™ stands out as the only oral liquid formulation of losartan with FDA approval, available in a convenient 165 mL bottle, which features a peppermint flavor and does not require refrigeration. This product has a shelf life of 18 months under room temperature conditions, ensuring its effectiveness and usability for patients and caregivers.
About Scienture Holdings, Inc.
SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) operates through its subsidiaries, including Scienture, LLC and Integra Pharma Solutions, LLC, focusing on creating unique pharmaceutical products tailored to meet unmet market needs. Integra Pharma Solutions is involved in the distribution of various pharmaceutical products to healthcare entities across the United States. Meanwhile, Scienture, LLC is dedicated to developing specialty pharmaceutical ventures that enhance patient and healthcare system outcomes.
These unique products encompass a range of therapeutic areas, catering to diverse market demands while fulfilling the company's commitment to improving healthcare delivery.
Frequently Asked Questions
What is Arbli™ and its significance?
Arbli™ is an FDA-approved oral liquid formulation of losartan that addresses unmet medical needs, particularly for patients who cannot take traditional tablet forms.
Why has Scienture Holdings temporarily paused ELOC draws?
The company decided to pause additional draws to ensure sufficient capitalization and to demonstrate confidence as they transition to the commercial launch of Arbli™.
When is the anticipated launch date for Arbli™?
Arbli™ is expected to be launched in the U.S. market in the third quarter of 2025.
What are the primary uses of Arbli™?
Arbli™ is indicated for treating hypertension, reducing stroke risks, and managing diabetic nephropathy in certain patients with type 2 diabetes.
How does Scienture Holdings distribute its products?
Scienture Holdings distributes its pharmaceutical products through subsidiaries to healthcare markets, including government organizations, hospitals, and pharmacies across the nation.
